Instem plc
("Instem" or "the Company")
Grant of PDMR Options
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Phil Reason (Chief Executive Officer) and Nigel Goldsmith (Chief Financial Officer) have each been granted awards of nil-cost options over 4,833 and 2,165 Ordinary Shares respectively under the Instem plc 2018 Long Term Incentive Plan ("LTIP"). These options will ordinarily vest and become exercisable on 1 January 2025 pursuant to the rules of the LTIP.
After these grants of options, Mr Reason and Mr Goldsmith hold options over a total of 133,649 and 261,696 Ordinary Shares, respectively.
For further information, please contact:
| Instem plc | via Walbrook |
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
| Peter Steel Rachel Hayes Alex Bond |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Broker) |
+44 (0) 20 7710 7600 |
| Ben Maddison |
|
| Alex Price
|
|
|
Walbrook Financial PR |
+44 (0) 20 7933 8780 |
| Tom Cooper | instem@walbrookpr.com |
| Nick Rome
|
|
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a)
| Name
| Phil Reason | |||
| 2 | Reason for the notification | ||||
| a)
| Position/status | Chief Executive Officer | |||
| b)
| Initial notification /Amendment | Initial | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a)
| Name
| Instem plc | |||
| b)
| LEI
| 213800PILYUFNNROQX68 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
| Description of the financial instrument, type of instrument | Grant of nil cost options under the Company's LTIP | |||
|
|
| ||||
| Identification code | GB00B3TQCK30 | ||||
|
|
| ||||
| b)
| Nature of the transaction |
| |||
| c)
| Price(s) and volume(s) |
|
|
|
|
|
|
| Price | Volume(s) |
| |
|
|
| Nil | 4,833 |
| |
|
|
|
|
|
| |
| d)
| Aggregated information |
| |||
|
|
| ||||
| - Aggregated volume | N/A - Single transaction | ||||
|
|
| ||||
| - Price |
| ||||
|
|
| ||||
| e)
| Date of the transaction | 7th March 2022 | |||
| f) | Place of the transaction | Off-market transaction | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a)
| Name
| Nigel Goldsmith | |||
| 2 | Reason for the notification | ||||
| a)
| Position/status | Chief Financial Officer | |||
| b)
| Initial notification /Amendment | Initial | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a)
| Name
| Instem plc | |||
| b)
| LEI
| 213800PILYUFNNROQX68 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of 10p each | |||
|
|
| ||||
| Identification code | GB00B3TQCK30 | ||||
|
|
| ||||
| b)
| Nature of the transaction | Grant of nil cost options under the Company's LTIP | |||
| c)
| Price(s) and volume(s) |
|
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
|
| Nil | 2,165 |
| |
|
|
|
|
|
| |
| d)
| Aggregated information | N/A - Single Transaction | |||
|
|
| ||||
| - Aggregated volume |
| ||||
|
|
| ||||
| - Price |
| ||||
|
|
| ||||
| e)
| Date of the transaction | 11th March 2022 | |||
| f) | Place of the transaction | Off-market transaction | |||
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
